Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.[ Read More ]
The intrinsic value of one ALKS stock under the base case scenario is HIDDEN Compared to the current market price of 28.2 USD, Alkermes plc is HIDDEN
Current Assets | 1.49 B |
Cash & Short-Term Investments | 773 M |
Receivables | 333 M |
Other Current Assets | 379 M |
Non-Current Assets | 651 M |
Long-Term Investments | 39.9 M |
PP&E | 318 M |
Other Non-Current Assets | 292 M |
Current Liabilities | 520 M |
Accounts Payable | 65.6 M |
Short-Term Debt | 8.75 M |
Other Current Liabilities | 446 M |
Non-Current Liabilities | 413 M |
Long-Term Debt | 363 M |
Other Non-Current Liabilities | 49.9 M |
Revenue | 1.66 B |
Cost Of Revenue | 289 M |
Gross Profit | 1.37 B |
Operating Expenses | 996 M |
Operating Income | 414 M |
Other Expenses | 58.4 M |
Net Income | 356 M |
Net Income | 356 M |
Depreciation & Amortization | 74.9 M |
Capital Expenditures | -48 M |
Stock-Based Compensation | 101 M |
Change in Working Capital | -36.7 M |
Others | -6.12 M |
Free Cash Flow | 353 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
6 days ago
Nov 11, 2024
|
Sell 1.77 M USD
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer |
- 58996
|
30.0796 USD |
1 week ago
Nov 06, 2024
|
Sell 309 K USD
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer |
- 10471
|
29.5262 USD |
8 months ago
Mar 18, 2024
|
Sell 293 K USD
|
Nichols Christian Todd
SVP, Chief Commercial Officer |
- 10417
|
28.1021 USD |
8 months ago
Feb 27, 2024
|
Sell 75.9 K USD
|
Parisi Samuel Joseph
VP, Finance (Interim PAO) |
- 2559
|
29.65 USD |
9 months ago
Feb 15, 2024
|
Sell 85.7 K USD
|
LAURENCIN CATO T
Director |
- 2690
|
31.85 USD |
1 year ago
Jun 08, 2023
|
Sell 84 K USD
|
LAURENCIN CATO T
Director |
- 2638
|
31.85 USD |
1 year ago
Jun 07, 2023
|
Sell 88.2 K USD
|
LAURENCIN CATO T
Director |
- 2800
|
31.5 USD |
1 year ago
May 30, 2023
|
Sell 785 K USD
|
Nichols Christian Todd
SVP, Chief Commercial Officer |
- 27134
|
28.9254 USD |
1 year ago
May 09, 2023
|
Sell 1.29 M USD
|
Wysenski Nancy
Director |
- 41250
|
31.2433 USD |
2 years ago
Nov 14, 2022
|
Bought 816 K USD
|
Daglio David Angelo Jr.
Director |
+ 35000
|
23.3067 USD |
2 years ago
Jun 21, 2022
|
Sell 211 K USD
|
Nichols Christian Todd
SVP, Chief Commercial Officer |
- 7474
|
28.2584 USD |